Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2024-05-16 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
Regulatory Filings Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific, positive development regarding a clinical trial (DMC recommendation for the NATiV3 Phase III trial). It provides key highlights, context about the drug (lanifibranor), and contact information. This format strongly indicates an immediate public disclosure of material information, which aligns best with an Earnings Release (ER) if it were financial results, or more generally, a Regulatory Filing (RNS) if it's a non-financial, material update. Since it is a press release announcing a clinical trial milestone, and not a full financial report (10-K, IR) or a management discussion (MDA), the most appropriate category for a material, non-financial regulatory announcement that isn't covered by other specific codes (like DIRS, DIV, etc.) is the general Regulatory Filings category (RNS). It is not an ER because it focuses on clinical data, not period-end financial results.
2024-05-16 English
Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez l
Regulatory Filings Classification · 95% confidence The document is an announcement by Inventiva dated May 13, 2024, detailing the publication of complementary results from their Phase IIb NATIVE clinical study in the journal 'Nature Communications'. The text focuses on the positive impact of the drug lanifibranor on cardiometabolic health markers in MASH/NASH patients. It includes detailed statistical tables comparing treatment groups and quotes from key medical personnel regarding the study findings and publication. Since the document is an announcement about the publication of clinical study results, and it is not the full Annual Report (10-K), a standalone Audit Report (AR), or a general Earnings Release (ER), it best fits the category for Investor Presentations (IP) or potentially Regulatory Filings (RNS) if no better fit exists. Given the detailed nature of the scientific results being presented to investors/the public, 'Investor Presentation' (IP) is a strong candidate, as these announcements often serve as the primary vehicle for disseminating detailed trial data outside of formal regulatory filings. However, since this is specifically an announcement *about* a publication, and it is not a formal presentation deck, the most accurate classification for a press release detailing scientific/clinical updates is often 'Regulatory Filings' (RNS) as a broad category for material non-financial announcements, or if we consider the content as a detailed update on clinical progress, it aligns closely with the spirit of an Investor Presentation (IP) or a detailed press release. Given the context of financial reporting databases, press releases detailing clinical trial results are often categorized under RNS if they don't fit a specific financial report type. However, the content is highly scientific and promotional towards investors, making IP plausible. Let's re-evaluate the definitions. It is not a formal presentation (IP), nor is it a short announcement of a report (RPA). It is a detailed press release announcing scientific data. In many databases, detailed clinical updates like this fall under RNS (Regulatory Filings/Announcements) or sometimes a specific clinical update code if available. Since RNS is the general regulatory announcement fallback, and this is a material announcement, I will select RNS. If the document were a slide deck, IP would be correct. Since it is a press release detailing scientific findings, RNS is the most appropriate general regulatory announcement category.
2024-05-13 French
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with
Earnings Release Classification · 92% confidence The document is an announcement by Inventiva dated May 13, 2024, detailing the publication of additional results from its NATIVE Phase IIb clinical trial in the scientific journal *Nature Communications*. The text focuses on clinical data, statistical tables comparing treatment arms, expert commentary, and publication details. This structure—announcing positive clinical trial results and referencing a scientific publication—is characteristic of an Earnings Release (ER) or a general press release summarizing scientific findings. Since it is a detailed announcement of clinical trial results (not just the initial high-level earnings figures, nor a full transcript, nor a formal regulatory filing like a 10-K), it fits best as an Earnings Release (ER) which often includes significant operational/clinical updates, or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format, ER is the closest fit for disseminating key performance/study results to the market. However, given the focus is purely on scientific publication and clinical data rather than quarterly financial performance highlights, it is a scientific/clinical update. In the provided definitions, 'ER' (Earnings Release) is the closest fit for a major periodic announcement of results, even if clinical rather than purely financial. If a more specific 'Clinical Trial Result Announcement' existed, that would be preferred. Given the options, ER is the most appropriate category for a major periodic announcement of study outcomes to investors, though it is borderline with RNS/LTR if viewed strictly as a scientific disclosure. Since it is a formal announcement of study outcomes, ER is selected over the general RNS. FY 2024
2024-05-13 English
Franchissement de seuil
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" which translates to a declaration of crossing a threshold, specifically related to share ownership thresholds mandated by French commercial law (Code de commerce). It details that UBS Group AG crossed the 5% capital threshold of INVENTIVA on April 17, 2024, and provides a breakdown of shares held directly and indirectly. This type of filing, reporting changes in significant share ownership by an entity or individual, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory disclosure, not a general announcement of a report (RPA) or a miscellaneous filing (RNS).
2024-04-24 French
Franchissement de seuil
Major Shareholding Notification Classification · 98% confidence The document is dated April 22, 2024, and is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" (Declaration of crossing a threshold). It explicitly states that UBS Group AG crossed below the 5% threshold of INVENTIVA's capital on April 16, 2024, due to an off-market share transfer. This type of filing, reporting changes in significant share ownership crossing regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a regulatory filing, MRQ is more specific than the general RNS category.
2024-04-23 French
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
Report Publication Announcement Classification · 100% confidence The document is a press release announcing the filing of the company's 2023 Universal Registration Document and 2023 Annual Report on Form 20-F. It does not contain the actual financial statements or the full report itself, but rather informs the public that these documents have been filed with the AMF and SEC and provides links to access them. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). FY 2023
2024-04-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.